Skip navigation.
The University of Georgia College of Veterinary Medicine Home
Ralph Tripp - Tripp Lab, UGA

Viral Immunology:Tripp Laboratory

Ralph A. Tripp, PhD

Professor and Georgia Research Alliance Eminent Scholar

Dr. Raplh Tripp

ratripp@uga.edu

Research Interests

The research interest of our group is to develop translational disease intervention strategies for important human viruses and emerging infectious diseases of zoonotic origin. Our BSL2, BSL3 and BSL3Ag+ laboratories develop platform enabling technologies in pathogen biosensing using nanotechnology-based approaches, antiviral drugs using small molecule and RNAi-based drugs, and animal and human vaccines using state-of-the-art technologies with our in-house pilot GMP vaccine facility. In parallel, we investigate the mechanisms of immunity and disease pathogenesis associated with infection to better understand the conceptual and functional differences between innate and adaptive immune responses that provide the foundation necessary to facilitate vaccine and antiviral therapeutic protocols. The laboratories leverage the talents of academic, government and industry partners to promote ‘bench-to-bedside’ and ‘bench-to-barnyard’ vaccines and therapeutics.

(Back to PIs)

Vision

To understand the dynamics of the host response to infection that will provide new strategies for resolving disease through the development of cutting edge treatments or vaccines. These studies will facilitate training of new scientists and scientists with diverse backgrounds who will be able to communicate their findings to industry, the public, and the academic community, to help make Georgia the preeminent center for vaccine research and development.

(Back to PIs)

In the Lab

The fundamental goals of the laboratory are to facilitate disease intervention strategies that control or prevent important human viruses and emerging infectious diseases (EID) of zoonotic origin that pose significant health risks to human and/or animal hosts. The specific aims of the lab are to: 1) Develop a discovery-to-control continuum for the development and utilization of new and improved therapeutics, diagnostics and vaccines against these classes of pathogens, 2) Facilitate the interaction and collaboration of investigators and industry working on related diseases allowing for the cross-fertilization of ideas and multi-disciplinary approaches,  3) Develop national and international collaborations that allow for scientific exchanges and leveraging of talents, and 4) Promote the funding of these research efforts through governmental support, and develop industrial support for projects of commercial interest and/or the commercialization of products of research conducted in the lab.

(Back to PIs)

Recent Publications

Search PubMed for Tripp, RA

(Back to PIs)

This page last updated November 8, 2011 .